WASHINGTON, DC (August 6, 2021) – Today, the Institute for Gene Therapies (IGT) Chairman Congressman Erik Paulsen issued the following statement regarding the Fiscal Year 2022 appropriations bill for the Department of Agriculture and Food and Drug Administration:
The Institute for Gene Therapies applauds members of the Senate Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Subcommittee for prioritizing the development of cell and gene therapies in the fiscal year 2022 appropriations bill for the Department of Agriculture and Food and Drug Administration. By including new funding for FDA’s Center for Biologics Evaluation and Research Office of Tissues and Advanced Therapies, the Committee recognizes the transformative potential of cell and gene therapies for patients with life-threatening diseases and demonstrates an understanding of FDA’s vital role in advancing this nascent field of medicine. Specifically, the funds will be directed to increasing staff capacity and facilitating dialogue to advance cell and gene therapies through later stages of development. We look forward to continued progress on this issue as the House and Senate work to pass an appropriations package.
The Committee’s report is available here (page 130)
Full text of the bill is available here
About the Institute for Gene Therapies
The Institute for Gene Therapies brings together experts from across the healthcare system to advocate for a modernized policy framework that encourages innovations and promotes patient access to the treatments they need. We represent innovators and patients, business leaders and academics working to ensure policies reflect medical advances, creating a new reality for patients. Follow us on Twitter @gene_therapies.